Market Cap
$1.1T
LLY
ELI LILLY & Co
$1,143.30 ▼ -0.57%
Prev close $1,149.85Market cap$1.1T
ConsensusBuy
12-mo target$1,328.83 (+15.7%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)32 New Institutional Positions18 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on LLY right now — valuation, ownership and activity at a glance.
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (79%)
Inst. Holders
50 funds
Inst. Value
$754.7B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $34.6M sell
Insider Net $
-$34.6M
Social Sentiment
62° Warm
SEC Reports
14
Press Releases
1
Congressional
16 trades
Price chart 30d -1.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that th
Sep 23, 2026 Event
ONSWIK
Original Approval — Type 1 - New Molecular Entity — INJECTABLE
Sep 21, 2026 Insider
Alvarez Ralph was granted 10.659 shares
Director @ $1,164.89 ($12.4K)
Sep 21, 2026 Insider
Sulzberger Gabrielle was granted 4.257 shares
Director @ $1,164.89 ($5.0K)
Sep 21, 2026 Insider
Sep 11, 2026 Press Fyrwald J Erik was granted 8.513 shares
Director @ $1,164.89 ($9.9K)
Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental hea
Impact 5/10
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied
COURT-RULING — Impact 4/10
Sep 8, 2026 Event
Eli Lilly and Company v. Mochi Health Corp. et al
Court ruling (cand) — Docket: 3:25-cv-03534
Analyst ratings buy % +5.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
79% rate it Buy or better · 38 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Sep 22, 2026 | TD Cowen | REITERATE | Buy | 56% |
| Sep 18, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Sep 10, 2026 | HSBC | MAINTAIN | Reduce | 55% |
| Aug 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 6, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 6, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Jul 15, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 14, 2026 | Bernstein | MAINTAIN | Outperform | 51% |
| Jul 13, 2026 | UBS | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 11 | 19 | 7 | 1 | 0 | 79% | |
| Aug 1, 2026 | 11 | 19 | 7 | 1 | 0 | 79% | |
| Jul 1, 2026 | 11 | 19 | 7 | 1 | 0 | 79% | |
| Jun 1, 2026 | 11 | 20 | 7 | 1 | 0 | 79% | |
| May 1, 2026 | 11 | 19 | 8 | 1 | 0 | 77% | |
| Apr 1, 2026 | 12 | 18 | 8 | 1 | 0 | 77% | |
| Mar 1, 2026 | 12 | 18 | 9 | 0 | 0 | 77% | |
| Feb 1, 2026 | 11 | 16 | 10 | 0 | 0 | 73% |
Price targets
Where 29 covering analysts think LLY trades over the next 12 months.
$1,328.83 +15.7% upside Buy
Current$1,148.29 Low$930.00 Median$1,385.00 High$1,600.00 29 analysts
$930.00$1,600.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Social media sentiment mood +36.4%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
62°
Warm
BearishNeutralBullish
Recent posts
Started grading my alerts on actual bid/ask instead of mid and wow
▲ 1 · 💬 5· ⚡ 0.5
Why did this call option go up when LLY is down?
▲ 1 · 💬 1· ⚡ 0.5
Why is call option up when LLY is down?
▲ 1 · 💬 0· ⚡ 0.5
How is my starter setup
▲ 1 · 💬 7· ⚡ 0.5
Why are people here so against investing in single stocks?
▲ 1 · 💬 7· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 4 bullish, 1 bearish, 0 mixed, 9 neutral · avg impact 4.1/10.Plus 1 press releases.
NEUTRALCOURT-RULING4/10
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in pa
Sep 9, 2026
NEUTRALCLUSTER3/10
Two senior executives at Eli Lilly sold a combined $10.01M in stock over the past week, including th
Aug 19, 2026
NEUTRALCLUSTER3/10
Two senior Eli Lilly executives (SVP Finance/CAO and EVP GC/Secretary) sold a combined $8.32M in ope
Aug 12, 2026
NEUTRALCOURT-RULING3/10
The court issued a pretrial order in Nektar Therapeutics v. Eli Lilly & Co, setting a jury trial for
Aug 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has appr
Oct 1, 2026
Clinical Trial
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Phase Phase 3 — COMPLETED
Sep 30, 2026
short_volume
Short Volume: LLY — 59.5% short (0.7M / 1.2M)
Short: 704,928 | Exempt: 91 | TRF Vol: 1,184,340 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
Clinical Trial
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Phase Phase 2 — COMPLETED
Sep 29, 2026
clinical_trial_readout
Results Pending: LY3841136 (Phase 2) — Completed 90d ago
Trial: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesit
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $9.96 | $9.23–$11.31 | 41.8% | +0.9% | 13↑ 2↓ | $22.4B | 17 |
| Next Q | $10.06 | $9.15–$11.64 | 33.5% | +0.9% | 7↑ 8↓ | $23.3B | 17 |
| Current FY | $36.95 | $35.53–$40.77 | 52.6% | +0.7% | 13↑ 10↓ | $88.5B | 27 |
| Next FY | $47.59 | $40.73–$54.94 | 28.8% | +0.7% | 19↑ 4↓ | $102.1B | 27 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $9.956 | — |
| 7d ago | $9.932 | +0.024 |
| 30d ago | $9.871 | +0.085 |
| 60d ago | $9.480 | +0.476 |
| 90d ago | $9.417 | +0.539 |
Institutional ownership
Which big funds own LLY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $754.7B total value (629,920,037 shares) as of 2026-Q2. Top holders: LILLY, BlackRock,, VANGUARD. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| LILLY ENDOWMENT INC | 90,376,978 | $108.4B | 14.4% | — |
| BlackRock, Inc. | 67,540,400 | $81.0B | 10.7% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 53,528,868 | $64.2B | 8.5% | — |
| PNC FINANCIAL SERVICES GROUP, INC. | 51,322,720 | $61.6B | 8.2% | — |
| STATE STREET CORP | 36,215,754 | $43.4B | 5.8% | — |
| FMR LLC | 28,462,475 | $34.1B | 4.5% | — |
| Capital Research Global Investors | 20,873,140 | $25.0B | 3.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 20,859,217 | $25.0B | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 20,310,858 | $24.3B | 3.2% | — |
| MORGAN STANLEY | 16,226,398 | $19.5B | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 11,471,413 | — | $13.8B |
| AMERICAN CENTURY COMPANIES INC | ADD | 1,845,922 | 2,354,837 | +27.6% | $2.8B |
| BARCLAYS PLC | TRIM | 1,563,625 | 1,143,891 | -26.8% | $1.4B |
| CITADEL ADVISORS LLC | DOUBLED | 241,714 | 945,456 | +291.1% | $1.1B |
| POLEN CAPITAL MANAGEMENT LLC | TRIM | 914,557 | 666,912 | -27.1% | $799.9M |
| Corient Private Wealth LP | ADD | 654,787 | 1,206,575 | +84.3% | $764.1M |
| Quantinno Capital Management LP | ADD | 433,880 | 547,546 | +26.2% | $656.7M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | DOUBLED | 144,813 | 526,202 | +263.4% | $631.1M |
| PARNASSUS INVESTMENTS, LLC | TRIM | 935,462 | 525,464 | -43.8% | $630.3M |
| Assenagon Asset Management S.A. | TRIM | 1,550,234 | 501,025 | -67.7% | $600.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$34.6M — $0.00 bought, $34.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Alvarez Ralph | Director | AWARD | 10.659 | $1,164.89 | $12.4K |
| Sep 21, 2026 | Sulzberger Gabrielle | Director | AWARD | 4.257 | $1,164.89 | $5.0K |
| Sep 21, 2026 | Fyrwald J Erik | Director | AWARD | 8.513 | $1,164.89 | $9.9K |
| Sep 21, 2026 | LUCIANO JUAN R | Director | AWARD | 13.664 | $1,164.89 | $15.9K |
| Sep 9, 2026 | Seymour Melissa | EVP, Global Quality | GIFT | 12 | — | — |
| Sep 2, 2026 | Hernandez Edgardo | EVP & Pres., Mfg. Operations | GIFT | 13 | — | — |
| Sep 2, 2026 | Dozier Eric | EVP, Chief People Officer | GIFT | 216 | — | — |
| Aug 17, 2026 | Sulzberger Gabrielle | Director | AWARD | 4.191 | $1,183.16 | $5.0K |
| Aug 17, 2026 | Alvarez Ralph | Director | AWARD | 10.495 | $1,183.16 | $12.4K |
| Aug 17, 2026 | Fyrwald J Erik | Director | AWARD | 8.382 | $1,183.16 | $9.9K |
Congressional trades
LLY trades disclosed by members of Congress, with disclosure delay.
10 members · 8 buys / 8 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Dan Newhouse | R | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Jul 20, 2026(11d) |
| Jul 1, 2026 | Michael Rulli | R | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Aug 10, 2026(41d) |
| Jun 10, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $50,001 - $100,000 | Eli Lilly and Co | Jul 3, 2026(24d) |
| Jun 2, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | Jul 8, 2026(37d) |
| Apr 8, 2026 | Lizzie Fletcher | D | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | May 1, 2026(24d) |
| Apr 2, 2026 | Byron Donalds | R | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | May 14, 2026(43d) |
| Apr 2, 2026 | Byron Donalds | R | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | May 14, 2026(43d) |
| Mar 13, 2026 | Gilbert Cisneros | D | HOUSE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Apr 8, 2026(27d) |
| Feb 26, 2026 | David Taylor | R | HOUSE | BUY | $1,001 - $15,000 | Eli Lilly and Co | Mar 9, 2026(12d) |
| Feb 13, 2026 | Angus King | O | SENATE | SELL | $1,001 - $15,000 | Eli Lilly and Co | Mar 24, 2026(39d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LLY.
Shares short
7,519,918
Settlement Sep 15, 2026
Change vs prior
-4.7%
Semi-monthly cycle
Days to cover
3.4
At avg daily volume
Of shares outstanding
≈0.8%
Estimate — not % of float
All LLY filing & press-release reports (15)
- PRESS-RELEASE reportSep 11, 2026
- COURT-RULING reportSep 9, 2026
- CLUSTER reportAug 19, 2026
- CLUSTER reportAug 12, 2026
- COURT-RULING reportAug 8, 2026
- COURT-RULING reportAug 6, 2026
- 8-K reportAug 5, 2026
- COURT-RULING reportAug 1, 2026
- COURT-RULING reportJul 31, 2026
- PRESS-RELEASE reportJul 22, 2026
- COURT-RULING reportJul 15, 2026
- COURT-RULING reportJul 14, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportApr 16, 2026
- DEFA14A reportMar 20, 2026